4D Molecular Therapeutics Gets Termination Notice From Roche
June 24 2021 - 09:33AM
Dow Jones News
By Chris Wack
4D Molecular Therapeutics Inc. said it received a notice of
termination of the collaboration and license agreement by 4D-110
licensee Roche resulting in full rights to 4D-110 for choroideremia
reverting to 4D Molecular.
The company said Roche requested that 4D Molecular end the
Roche-funded 4D-110 trial in advanced choroideremia patients as a
result of Roche's assessment of a change in the risk-benefit
profile.
Roche sent a notice of termination without cause effective Sept.
16, with 4D Molecular regaining full rights to 4D-110.
4D Molecular said it hasn't changed its position on the
potential of 4D-110 for choroideremia, and intends to continue
clinical development. The company said it plans to submit to the
Food and Drug Administration safety and efficacy data from the
completed Phase 1 clinical trial along with a new clinical study
protocol as soon as possible.
The company said it will conclude the Roche-funded clinical
trial under the collaboration and plans to subsequently transfer
previously treated patients onto a company-sponsored long-term
follow-up study to continue monitoring biologic activity endpoints,
safety and tolerability.
4D Molecular Therapeutics shares were down 7% to $23 in
premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
June 24, 2021 09:25 ET (13:25 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Feb 2024 to Mar 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2023 to Mar 2024